Evidence map›Paper›PMID 41811882›Full record

ReviewJournal of immunology research2026

Myeloid-Derived Suppressor Cells: Immunoregulatory Roles and Therapeutic Prospects in Immune-Mediated Hematological Disorders.

Qi Liu, Kunpeng Zhang, Shun He, Xinru Jia, Jingjing Liu, Dijiong Wu, Baodong Ye

Abstract readReview
In one paragraph

Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qi LiuDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0000-0002-5075-6717
Kunpeng ZhangDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0009-0001-6917-2789
Shun HeSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, zcmu.edu.cn.ORCID https://orcid.org/0009-0007-3612-0505
Xinru JiaDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0000-0003-1352-712X
Jingjing LiuDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0009-0004-0780-2345
Dijiong WuDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0000-0003-2338-9365
Baodong YeDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com.ORCID https://orcid.org/0000-0001-5912-2633

Funding

National Natural Science Foundation of China 82174138National Natural Science Foundation of China 82274273Specific Program of Scientific Research of Zhejiang Chinese Medicine University for Affiliated Hospital 2025FSYYZX04
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that have been increasingly defined and characterized over the past two decades, known for their remarkable capacity to expand and exert immunosuppressive effects in various pathological contexts, such as malignancies, infections, and inflammatory diseases. Although MDSCs have attracted significant attention in tumor immunology, their multifaceted roles in immune-mediated hematological disorders remain comparatively understudied and less understood, especially in contrast to their well-documented functions in both solid and hematological malignancies. This review delves into the biological characteristics and functional mechanisms of MDSCs, as well as their dual immunomodulatory roles in various immune-mediated hematological disorders such as immune thrombocytopenia and aplastic anemia. Substantial evidence indicates that in these diseases, the expansion, recruitment, and function of MDSCs are significantly altered, with their levels closely correlated to disease activity. Based on these findings, we further explore the therapeutic potential of targeting MDSCs. Manipulating MDSCs offers a pioneering perspective for the development of next-generation immunotherapies, which holds promise for reshaping the current treatment landscape of immune-mediated hematological disorders.

Indexed as

Hematologic DiseasesMyeloid-Derived Suppressor CellsAnimalsHost-Directed TherapyHumansImmunomodulationImmunotherapyimmune-mediated hematological diseasesimmunosuppressionmyeloid-derived suppressor cells

Identifiers

PMID41811882
PMCPMC13140331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.